These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 29090582)
1. Variability of Complement Response toward Preclinical and Clinical Nanocarriers in the General Population. Benasutti H; Wang G; Vu VP; Scheinman R; Groman E; Saba L; Simberg D Bioconjug Chem; 2017 Nov; 28(11):2747-2755. PubMed ID: 29090582 [TBL] [Abstract][Full Text] [Related]
2. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. Gifford G; Vu VP; Banda NK; Holers VM; Wang G; Groman EV; Backos D; Scheinman R; Moghimi SM; Simberg D J Control Release; 2019 May; 302():181-189. PubMed ID: 30974134 [TBL] [Abstract][Full Text] [Related]
3. Complement opsonization of nanoparticles: Differences between humans and preclinical species. Li Y; Wang G; Griffin L; Banda NK; Saba LM; Groman EV; Scheinman R; Moghimi SM; Simberg D J Control Release; 2021 Oct; 338():548-556. PubMed ID: 34481928 [TBL] [Abstract][Full Text] [Related]
4. Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. Inturi S; Wang G; Chen F; Banda NK; Holers VM; Wu L; Moghimi SM; Simberg D ACS Nano; 2015 Nov; 9(11):10758-68. PubMed ID: 26488074 [TBL] [Abstract][Full Text] [Related]
5. Wang G; Griffin JI; Inturi S; Brenneman B; Banda NK; Holers VM; Moghimi SM; Simberg D Front Immunol; 2017; 8():151. PubMed ID: 28239384 [TBL] [Abstract][Full Text] [Related]
6. Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum. Banda NK; Mehta G; Chao Y; Wang G; Inturi S; Fossati-Jimack L; Botto M; Wu L; Moghimi SM; Simberg D Part Fibre Toxicol; 2014 Nov; 11():64. PubMed ID: 25425420 [TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts. Li Y; Saba L; Scheinman RI; Banda NK; Holers M; Monte A; Dylla L; Moghimi SM; Simberg D ACS Nano; 2024 Oct; 18(42):28649-28658. PubMed ID: 39395006 [TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. Vu VP; Gifford GB; Chen F; Benasutti H; Wang G; Groman EV; Scheinman R; Saba L; Moghimi SM; Simberg D Nat Nanotechnol; 2019 Mar; 14(3):260-268. PubMed ID: 30643271 [TBL] [Abstract][Full Text] [Related]
9. High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties. Wang G; Inturi S; Serkova NJ; Merkulov S; McCrae K; Russek SE; Banda NK; Simberg D ACS Nano; 2014 Dec; 8(12):12437-49. PubMed ID: 25419856 [TBL] [Abstract][Full Text] [Related]
10. Feraheme (Ferumoxytol) Is Recognized by Proinflammatory and Anti-inflammatory Macrophages via Scavenger Receptor Type AI/II. Wang G; Serkova NJ; Groman EV; Scheinman RI; Simberg D Mol Pharm; 2019 Oct; 16(10):4274-4281. PubMed ID: 31556296 [TBL] [Abstract][Full Text] [Related]
11. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Chen F; Wang G; Griffin JI; Brenneman B; Banda NK; Holers VM; Backos DS; Wu L; Moghimi SM; Simberg D Nat Nanotechnol; 2017 May; 12(4):387-393. PubMed ID: 27992410 [TBL] [Abstract][Full Text] [Related]
12. An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil®, Caelyx®, DOXOrubicin, and SinaDoxosome. Wibroe PP; Ahmadvand D; Oghabian MA; Yaghmur A; Moghimi SM J Control Release; 2016 Jan; 221():1-8. PubMed ID: 26608877 [TBL] [Abstract][Full Text] [Related]
13. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes. Hsieh YC; Wang HE; Lin WW; Roffler SR; Cheng TC; Su YC; Li JJ; Chen CC; Huang CH; Chen BM; Wang JY; Cheng TL; Chen FM Theranostics; 2018; 8(11):3164-3175. PubMed ID: 29896310 [No Abstract] [Full Text] [Related]
14. Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice. Kato Y; Zhu W; Backer MV; Neoh CC; Hapuarachchige S; Sarkar SK; Backer JM; Artemov D Pharm Res; 2015 Nov; 32(11):3746-3755. PubMed ID: 26078000 [TBL] [Abstract][Full Text] [Related]
15. Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Simberg D; Park JH; Karmali PP; Zhang WM; Merkulov S; McCrae K; Bhatia SN; Sailor M; Ruoslahti E Biomaterials; 2009 Aug; 30(23-24):3926-33. PubMed ID: 19394687 [TBL] [Abstract][Full Text] [Related]
16. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma. Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935 [TBL] [Abstract][Full Text] [Related]
17. Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking. Wang G; Chen F; Banda NK; Holers VM; Wu L; Moghimi SM; Simberg D Front Immunol; 2016; 7():418. PubMed ID: 27777575 [TBL] [Abstract][Full Text] [Related]
18. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. Ishida T; Atobe K; Wang X; Kiwada H J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355 [TBL] [Abstract][Full Text] [Related]